medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2018, Número 1

<< Anterior Siguiente >>

Acta Med 2018; 16 (1)


Tapentadol, un nuevo horizonte en el tratamiento de la neuropatía diabética periférica dolorosa

Bueno AGM, Jiménez MV, German CI, Lazarini RJF, Galindo SJI

Idioma: Español
Referencias bibliográficas: 29
Paginas: 41-46
Archivo PDF: 141.37 Kb.


RESUMEN

La prevalencia de diabetes mellitus va en aumento y las complicaciones son cada vez más frecuentes, una de las más comunes es la neuropatía diabética periférica que se presenta de 30 a 50% en los pacientes; de 10 a 20% de éstos manifiestan dolor. El mecanismo por el cual se manifiesta el dolor no está claro, pero se ha asociado a estados crónicos de hiperglucemia y factores de riesgo cardiovascular. El dolor que se asocia a este padecimiento es crónico y difícil de manejar, aumenta la morbilidad y mortalidad, así como los costos en la salud. Hay estudios que indican que los opiáceos son los medicamentos más prescritos para el manejo del dolor crónico de este padecimiento, pero por sus efectos adversos los pacientes no se apegan al tratamiento, provocando su suspensión. Gracias a su doble acción el tapentadol, recientemente aprobado por la FDA para el manejo del dolor de la neuropatía diabética periférica, brinda un manejo eficaz del dolor, con disminución de los efectos adversos que se presentan comúnmente con los opioides. Es bien tolerado por los adultos mayores y no se ajusta en pacientes con enfermedad renal moderada o enfermedad hepática leve.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes. Can J Diabetes. 2015; 39 (4): 285-295.

  2. Games G, Hutchison A. Tapentadol-ER for the treatment of diabetic peripheral neuropathy. Consult Pharm. 2013; 28 (10): 672-675.

  3. Desai B, Freeman E, Huang E, Hung A, Knapp E, Breunig IM et al. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. Expert Rev Clin Pharmacol. 2014; 7 (2): 203-209.

  4. Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015; 29 (2): 212-217.

  5. Vinik AI. Clinical practice. Diabetic sensory and motor neuropathy. N Engl J Med. 2016; 374 (15): 1455-1464.

  6. Serrano-Atero MS, Peramo F, Cañas A, García-Saura P, Serrano-Álvarez C, Caballero J. Modulación descendente de la información nociceptiva (I). Rev Soc Esp Dolor. 2002; 9 (6): 382-390.

  7. Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016; 94 (3): 227-234.

  8. Hartemann A, Attal N, Bouhassira D, Dumont I, Gin H, Jeanne S et al. Painful diabetic neuropathy: diagnosis and management. Diabetes Metab. 2011; 37 (5): 377-388.

  9. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010; 14 (8): 781-783.

  10. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 2009; 31 (12): 2804-2818.

  11. Silverman RB, Candiotti KA, Gitlin MC. Tapentadol extended-release: a recent addition to our analgesic armamentarium. Pain Manag. 2012; 2 (5): 451-456.

  12. Christoph T, De Vry J, Tzschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett. 2010; 470 (2): 91-94.

  13. Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007; 32 (3): 163-169.

  14. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013; 16 (1): 27-40.

  15. Strick V. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists. Curr Med Res Opin. 2014; 30 (10): 2085-2092.

  16. Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract. 2015; 15 (5): 455-470.

  17. Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. J Opioid Manag. 2013; 9 (5): 343-356.

  18. Macedo KA, Nailor MD. Focus on tapentadol: role in the treatment of neuropathic pain. Formulary. 2013; 48: 395-402.

  19. Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther. 2015; 37 (1): 94-113.

  20. Mehra M, Merchant S, Gupta S, Potluri RC. Diabetic peripheral neuropathy: resource utilization and burden of illness. J Med Econ. 2014; 17 (9): 637-645.

  21. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27 (1): 151-162.

  22. Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2 (1): 67-75.

  23. Biondi DM, Xiang J, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015; 11 (5): 393-403.

  24. Veal FC, Peterson GM. Pain in the frail or elderly patient: does tapentadol have a role? Drugs Aging. 2015; 32 (6): 419-426.

  25. Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol. 2011; 666 (1-3): 72-79.

  26. Giorgi M. Tramadol and tapentadol hydrochloride: an old and a novel atypical opioid drug. An overview on their present applications. Med Weter. 2012; 68 (11): 643-646.

  27. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012; 13 (10): 1437-1449.

  28. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin. 2010; 26 (7): 1677-1684.

  29. Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013; 14 (10): 1227-124




2020     |     www.medigraphic.com